Novartis Bioventures Ltd's Net Worth
Estimate Recalculated Nov 11, 2024 01:40PM EST
Who is Novartis Bioventures Ltd
Novartis Bioventures Ltd has an estimated net worth of $57.7 Million. This is based on reported shares across multiple companies, which include Akouos, Inc., Forma Therapeutics Holdings, Inc.,, Galera Therapeutics, Inc., BICYCLE THERAPEUTICS plc, AILERON THERAPEUTICS INC, Altimmune, Inc., Aadi Bioscience, Inc., Ra Pharmaceuticals, Inc., Aeglea BioTherapeutics, Inc., PROTEOSTASIS THERAPEUTICS, INC., Tokai Pharmaceuticals Inc, Marina Biotech, Inc., Celladon Corp, and Akebia Therapeutics, Inc..
SEC CIK
Novartis Bioventures Ltd's CIK is 0001297709
Past Insider Trading and Trends
2016 was Novartis Bioventures Ltd's most active year for acquiring shares with 9 total transactions. Novartis Bioventures Ltd's most active month to acquire stocks was the month of January. 2011 was Novartis Bioventures Ltd's most active year for disposing of shares, totalling 79 transactions. Novartis Bioventures Ltd's most active month to dispose stocks was the month of December. 2014 saw Novartis Bioventures Ltd paying a total of $9,410,414.00 for 9,627,294 shares, this is the most they've acquired in one year. In 2020 Novartis Bioventures Ltd cashed out on 1,075,106 shares for a total of $8,957,134.68, their largest year based on trade value.
Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
